Ann Beliën

Rejuvenate Biomed is a clinical-stage platform and Belgian pipeline company founded in 2017 by Ann Belià « n. The company is committed to discovering and developing innovative combination drugs that can safely delay the onset of various age-related diseases. Rejuvenate Biomed has developed two proprietary drug discovery platforms, in silico combinagetm and in vivo celegagetm, to efficiently screen molecule libraries across a wide spectrum of age-related pathways. RJX-01, one of their drugs, is ready for a phase 2b clinical trial in sarcopenia, a musculoskeletal disease. The company is based on the Health Campus Limburg in Heusden-Zolder, BE. Ann Beliën has been the CEO since incorporation.